Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Allocetra,Undisclosed
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Enlivex Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Trial builds on encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was combined with PD1 checkpoint inhibition in a murine model of ov...
Brand Name : Allocetra
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
August 17, 2022
Lead Product(s) : Allocetra,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Enlivex Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?